Skip to main content

Biogen company profile

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

About Biogen

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).

The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

From Wikipedia, shared under CC BY-SA.

Company facts

TickerBIIB · Nasdaq
SectorBiotechnology
IndustryBiotechnology
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK875045

Officers and directors

NameRoleShares ownedLatest Form 4
Christopher A. ViehbacherPresident and CEO · Director111K · < 1%Option exercise, 6 Feb 2026
Susan H. AlexanderEVP Chief Legal Officer61.9K · < 1%Option exercise, 6 Feb 2026
Caroline D. DorsaDirector31.0K · < 1%Grant or award, 17 Jun 2025
Michael R. McDonnellEVP, Chief Financial Officer24.3K · < 1%Option exercise, 10 Feb 2025
Eric K. RowinskyDirector24.3K · < 1%Grant or award, 9 Jun 2026
Nicole C. MurphyHead of Pharm Ops and Tech19.7K · < 1%Open-market purchase, 12 Feb 2026
Stephen A. SherwinDirector13.7K · < 1%Grant or award, 9 Jun 2026
Robin C. KramerChief Financial Officer11.5KOption exercise, 6 Feb 2026
Jesus B. MantasDirector9.8K · < 1%Grant or award, 9 Jun 2026
William A. HawkinsDirector8.9K · < 1%Grant or award, 9 Jun 2026
Priya A. SinghalHead of Development8.0K · < 1%Sale under a 10b5-1 plan, 9 Feb 2026
Maria C. FreireDirector6.8K · < 1%Grant or award, 9 Jun 2026
Susan K. LangerDirector5.1K · < 1%Grant or award, 9 Jun 2026
Monish PatolawalaDirector3.7K · < 1%Grant or award, 9 Jun 2026
Lloyd MinorDirector2.4K · < 1%Sale under a 10b5-1 plan, 4 Aug 2026
Menelas PangalosDirector2.4K · < 1%Option exercise, 9 Jun 2026
Keeney AdamHead of Corporate Development—Option exercise, 1 May 2026
Godbout SeanChief Accounting Officer—Shares withheld for tax, 1 Apr 2026
Izzar RachidHead of Global Product Strat.—Option exercise, 6 Feb 2026
Grogan JaneHead of Research—Shares withheld for tax, 6 Feb 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

BIIB in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.